Targeting the MYC pathway to treat cancer
Targeting the MYC Pathway for the Treatment of Cancer
This study is looking at new ways to treat cancer by targeting a specific gene called MYC that helps tumors grow, and it aims to find better therapies that could help patients whose cancers are driven by this gene.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10914058 on NIH RePORTER |
What this research studies
This research focuses on developing new therapies that specifically target the MYC oncogene pathway, which is commonly activated in various human cancers. The principal investigator has extensive experience in understanding how MYC contributes to tumor growth and maintenance. By utilizing innovative techniques and mouse models, the research aims to explore both intrinsic tumor mechanisms and host immune responses to create effective cancer treatments. Patients may benefit from novel therapies that could potentially reverse or halt cancer progression linked to MYC addiction.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with cancers known to be driven by the MYC oncogene, such as certain types of leukemia, lymphoma, and solid tumors.
Not a fit: Patients with cancers that do not involve the MYC pathway or those with advanced-stage cancers that have already progressed beyond treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to groundbreaking therapies that directly target and inhibit the MYC oncogene, improving outcomes for cancer patients.
How similar studies have performed: While targeting the MYC pathway is a novel approach, previous research has shown promising results in understanding MYC's role in cancer, indicating potential for success in developing targeted therapies.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Felsher, Dean W — Stanford University
- Study coordinator: Felsher, Dean W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.